Sotera Health Company

NasdaqGS:SHC Stock Report

Market Cap: US$3.2b

Sotera Health Management

Management criteria checks 3/4

Sotera Health's CEO is Michael Petras, appointed in Jun 2016, has a tenure of 7.92 years. total yearly compensation is $9.70M, comprised of 10.8% salary and 89.2% bonuses, including company stock and options. directly owns 1.98% of the company’s shares, worth $63.22M. The average tenure of the management team and the board of directors is 3.6 years and 3.6 years respectively.

Key information

Michael Petras

Chief executive officer

US$9.7m

Total compensation

CEO salary percentage10.8%
CEO tenure7.9yrs
CEO ownership2.0%
Management average tenure3.6yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%

Mar 21
The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%

Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models

Mar 01
Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models

McIntyre Partnerships - Sotera Health Company: A Notable Outlier At A Discount

Feb 08

Is Sotera Health (NASDAQ:SHC) A Risky Investment?

Feb 06
Is Sotera Health (NASDAQ:SHC) A Risky Investment?

Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump

Dec 28
Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump

Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price

Dec 11
Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price

An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued

Sep 10
An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued

Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate

Jun 05
Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate

Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?

Feb 13
Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?

Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher

Nov 24
Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher

Sotera Health plunges 20% after jury awards $363M against its Sterigenics unit

Sep 19

Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 49%?

Sep 08
Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 49%?

Sotera Health GAAP EPS of $0.11 misses by $0.05, revenue of $266.64M beats by $10.34M

Aug 04

Is Sotera Health Company (NASDAQ:SHC) Trading At A 46% Discount?

May 09
Is Sotera Health Company (NASDAQ:SHC) Trading At A 46% Discount?

Returns On Capital Are Showing Encouraging Signs At Sotera Health (NASDAQ:SHC)

Mar 16
Returns On Capital Are Showing Encouraging Signs At Sotera Health (NASDAQ:SHC)

Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 38%?

Jan 19
Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 38%?

A Look At The Fair Value Of Sotera Health Company (NASDAQ:SHC)

Sep 24
A Look At The Fair Value Of Sotera Health Company (NASDAQ:SHC)

CEO Compensation Analysis

How has Michael Petras's remuneration changed compared to Sotera Health's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

US$55m

Dec 31 2023US$10mUS$1m

US$51m

Sep 30 2023n/an/a

-US$306m

Jun 30 2023n/an/a

-US$268m

Mar 31 2023n/an/a

-US$261m

Dec 31 2022US$17mUS$1m

-US$234m

Sep 30 2022n/an/a

US$121m

Jun 30 2022n/an/a

US$123m

Mar 31 2022n/an/a

US$135m

Dec 31 2021US$2mUS$1m

US$115m

Sep 30 2021n/an/a

US$36m

Jun 30 2021n/an/a

US$9m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$17mUS$728k

-US$39m

Sep 30 2020n/an/a

-US$23m

Jun 30 2020n/an/a

-US$28m

Mar 31 2020n/an/a

-US$29m

Dec 31 2019US$2mUS$700k

-US$21m

Compensation vs Market: Michael's total compensation ($USD9.70M) is above average for companies of similar size in the US market ($USD6.66M).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


CEO

Michael Petras (54 yo)

7.9yrs

Tenure

US$9,701,005

Compensation

Mr. Michael B. Petras Jr., serves as Chief Executive Officer at Sotera Health Company since June 20, 2016. He has been Chairman of the Board at Sotera Health Company since October 2020. He also served as t...


Leadership Team

NamePositionTenureCompensationOwnership
Michael Petras
Chairman & CEO7.9yrsUS$9.70m1.98%
$ 63.2m
Jonathan Lyons
Senior VP & CFOless than a yearUS$2.18mno data
Alexander Dimitrief
Senior VP1.5yrsUS$862.18k0.083%
$ 2.7m
Michael Rutz
President of Sterigenics3.6yrsUS$2.03m0.17%
$ 5.4m
Robert Hauzie
Chief Information Officer5.3yrsno datano data
Kristin Gibbs
Chief Marketing Officer7.5yrsno datano data
William Lehmann
Senior Vice President of Strategy & Corporate Development2.3yrsno datano data
Sally Turner
Chief Human Resources Officer5.3yrsno datano data
Kathleen Hoffman
Senior Vice President of Global Environmentalno datano datano data
Joseph Shrawder
President of Nelson Labs3.6yrsno datano data
Riaz Bandali
President of Nordion2.3yrsno datano data
Jason Peterson
VP & Treasurerno datano datano data

3.6yrs

Average Tenure

53.5yo

Average Age

Experienced Management: SHC's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Petras
Chairman & CEO7.9yrsUS$9.70m1.98%
$ 63.2m
David Donnini
Independent Director3.6yrsUS$302.50k0.0091%
$ 291.3k
James Neary
Independent Director3.6yrsUS$320.00k0.0091%
$ 291.3k
Constantine Mihas
Independent Director3.6yrsUS$305.00k0.0091%
$ 291.3k
Sean Cunningham
Independent Director3.6yrsUS$302.50k0.0091%
$ 291.3k
Vincent Petrella
Independent Director3.5yrsUS$325.00k0.0091%
$ 291.3k
Ann Klee
Independent Director3.6yrsUS$322.50k0.025%
$ 800.4k
Robert Knauss
Independent Director1.6yrsUS$300.00k0%
$ 0
Ruoxi Chen
Independent Director3.5yrsUS$302.50k0.0091%
$ 291.3k
David Wheadon
Independent Director3yrsUS$310.00k0.0071%
$ 225.2k
Karen Flynn
Independent Directorless than a yearUS$9.99kno data

3.6yrs

Average Tenure

60yo

Average Age

Experienced Board: SHC's board of directors are considered experienced (3.6 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.